EOLS
Evolus, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$9.30
+2.76%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+37.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Mar 20, 2026 | MOATAZEDI DAVID · director, officer: See Remarks | Sale | 13,669 | $4.75 |
| Mar 20, 2026 | Avelar Rui · officer: See Remarks | Sale | 3,119 | $4.75 |
| Mar 18, 2026 | MOATAZEDI DAVID · director, officer: See Remarks | Sale | 116,720 | $4.89 |
| Mar 18, 2026 | MOATAZEDI DAVID · director, officer: See Remarks | M-Exempt | 67,489 | $0.00 |
| Mar 18, 2026 | Avelar Rui · officer: See Remarks | Sale | 29,996 | $4.89 |
| Mar 18, 2026 | Avelar Rui · officer: See Remarks | M-Exempt | 8,804 | $0.00 |
| Feb 19, 2026 | Stewart Brady · director | A-Award | 45,559 | $0.00 |
| Feb 19, 2026 | Mitchell Tatjana · officer: Chief Financial Officer | A-Award | 177,471 | $4.39 |
| Feb 19, 2026 | White Albert G III · director | A-Award | 45,559 | $0.00 |
| Feb 19, 2026 | MOATAZEDI DAVID · director, officer: See Remarks | A-Award | 313,212 | $0.00 |
| Feb 19, 2026 | MOATAZEDI DAVID · director, officer: See Remarks | A-Award | 626,424 | $0.00 |
| Feb 19, 2026 | MOATAZEDI DAVID · director, officer: See Remarks | A-Award | 457,541 | $4.39 |
| Feb 19, 2026 | Malik Vikram · director | A-Award | 45,559 | $0.00 |
| Feb 19, 2026 | GILL DAVID N · director | A-Award | 45,559 | $0.00 |
| Feb 19, 2026 | Avelar Rui · officer: See Remarks | A-Award | 94,913 | $0.00 |
| Feb 19, 2026 | Avelar Rui · officer: See Remarks | A-Award | 138,649 | $4.39 |
| Feb 19, 2026 | Parschauer Karah Herdman · director | A-Award | 45,559 | $0.00 |
| Feb 19, 2026 | Mitchell Tatjana · officer: Chief Financial Officer | A-Award | 121,489 | $0.00 |
| Dec 29, 2025 | Avelar Rui · officer: See Remarks | Sale | 2,261 | $7.15 |
| Dec 29, 2025 | MOATAZEDI DAVID · director, officer: See Remarks | Sale | 10,539 | $7.15 |
| Oct 9, 2025 | Mitchell Tatjana · officer: Chief Financial Officer | A-Award | 104,603 | $0.00 |
| Oct 9, 2025 | Mitchell Tatjana · officer: Chief Financial Officer | A-Award | 143,403 | $7.61 |
| Aug 26, 2025 | Yamagishi-Dressler Tomoko · officer: Chief Marketing Officer | Sale | 5,722 | $7.51 |
| Aug 18, 2025 | Stewart Brady · director | Purchase | 30,000 | $6.82 |
| Jun 16, 2025 | MOATAZEDI DAVID · director, officer: See Remarks | Sale | 111,323 | $10 |
| Jun 16, 2025 | MOATAZEDI DAVID · director, officer: See Remarks | Sale | 16,582 | $9.89 |
| Jun 10, 2025 | White Albert G III · director | Purchase | 20,000 | $9.45 |
| May 14, 2025 | Avelar Rui · officer: See Remarks | Sale | 3,385 | $9.87 |
| May 14, 2025 | MOATAZEDI DAVID · director, officer: See Remarks | Sale | 15,787 | $9.87 |
| May 14, 2025 | Beaver Sandra · officer: Chief Financial Officer | Sale | 6,494 | $10 |
Institutional positioning
13F filings over the trailing two quarters
New 62Increased 112Reduced 86Sold out 20
| Filer | Action | Shares | Filed |
|---|---|---|---|
| NANTAHALA CAPITAL MANAGEMENT, LLC | Increased | 6,376,857 | May 15, 2026 |
| Nantahala Capital Management, LLC | Reduced | 5,602,021 | Aug 19, 2026 |
| BlackRock, Inc. | Increased | 4,840,828 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 4,290,383 | May 13, 2026 |
| BRAIDWELL LP | Increased | 3,155,209 | Aug 14, 2026 |
| BRAIDWELL LP | Unchanged | 3,105,209 | May 15, 2026 |
| Frazier Life Sciences Management, L.P. | Unchanged | 2,630,665 | Aug 14, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Unchanged | 2,630,665 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 2,470,408 | May 15, 2026 |
| PERCEPTIVE ADVISORS LLC | Increased | 2,459,285 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Reduced | 2,362,893 | Aug 13, 2026 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | Increased | 2,245,360 | May 14, 2026 |
| STONEPINE CAPITAL MANAGEMENT, LLC | Increased | 2,179,091 | May 14, 2026 |
| Stonepine Capital Management, LLC | Reduced | 2,010,162 | Aug 17, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 1,787,929 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Mar 20, 2026